<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS157837</article-id><article-id pub-id-type="doi">10.1101/2022.11.25.517977</article-id><article-id pub-id-type="archive">PPR576768</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sullivan</surname><given-names>David J</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Franchini</surname><given-names>Massimo</given-names></name><email>massimo.franchini@asst-mantova.it</email><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Senefeld</surname><given-names>Jonathon W.</given-names></name><email>senefeld.jonathon@mayo.edu</email><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Joyner</surname><given-names>Michael J.</given-names></name><email>joyner.michael@mayo.edu</email><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Casadevall</surname><given-names>Arturo</given-names></name><email>acasade1@jhu.edu</email><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Focosi</surname><given-names>Daniele</given-names></name><email>daniele.focosi@gmail.com</email><xref ref-type="aff" rid="A4">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Johns Hopkins Bloomberg School of Public Health and School of Medicine, Baltimore, MD 21218, USA</aff><aff id="A2"><label>2</label>Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy</aff><aff id="A3"><label>3</label>Department of Anesthesiology &amp; Perioperative Medicine, Mayo Clinic, Rochester, MN 55902, USA</aff><aff id="A4"><label>4</label>North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy</aff><author-notes><corresp id="CR1"><bold>Corresponding author</bold>: David Sullivan, 615 N. Wolfe St Rm W4606, Baltimore MD 21205. Tel 410 502 2522, fax 410 955 0105. <email>dsulliv7@jhmi.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>01</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>30</day><month>11</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nd/4.0/">CC BY-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Objectives</title><p id="P1">Recent 2022 SARS-CoV-2 Omicron variants, have acquired resistance to most neutralizing anti-Spike monoclonal antibodies authorized, and the BQ.1.* sublineages are notably resistant to all authorized monoclonal antibodies. Polyclonal antibodies from individuals both vaccinated and recently recovered from Omicron COVID-19 (VaxCCP) could retain new Omicron neutralizing activity.</p></sec><sec id="S2"><title>Methods</title><p id="P2">Here we reviewed BQ.1.* virus neutralization data from 920 individual patient samples from 43 separate cohorts defined by boosted vaccinations with or without recent Omicron COVID-19, as well as infection without vaccination.</p></sec><sec id="S3"><title>Results</title><p id="P3">More than 90% of the plasma samples from individuals in the recently (within 6 months) boosted VaxCCP study cohorts neutralized BQ.1.1, and BF.7 with 100% neutralization of WA-1, BA.4/5, BA.4.6 and BA.2.75. The geometric mean of the geometric mean 50% neutralizing titers (GM (GMT<sub>50</sub>) were 314, 78 and 204 for BQ.1.1, XBB.1 and BF.7, respectively. Compared to VaxCCP, plasma sampled from COVID-19 na√Øve subjects who also recently within 6 months received at least a third vaccine dose had about half of the GM (GMT<sub>50</sub>) for all viral variants.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">Boosted VaxCCP characterized by either recent vaccine dose or infection event within 6 months represents a robust, variant-resilient, passive immunotherapy against the new Omicron BQ.1.1, XBB.1 and BF.7 variants.</p></sec></abstract><kwd-group><kwd>convalescent plasma</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>BQ.1.1</kwd><kwd>XBB</kwd><kwd>BF.7: virus neutralization</kwd></kwd-group></article-meta></front><body><sec id="S5" sec-type="intro"><title>Introduction</title><p id="P5">In immunocompromised (IC) patients both passive immunotherapies and small molecule antivirals are often necessary to treat COVID-19 or eliminate persistently high SARS-CoV-2 viral load. Chronic, persistent viral loads increase both transmission and mutation risk, and prevent administration of the required immunosuppressive/antineoplastic therapies(<xref ref-type="bibr" rid="R1">1</xref>). Small molecule antivirals have not been formally validated for IC patients, who often have contraindications, and the convergent evolution of the Omicron variant of concern (VOC) has led to inefficacy of all the anti-Spike monoclonal antibodies (mAbs) authorized so far for both treatment or prevention, e.g. in the highly prevalent BQ.1.* sublineages(<xref ref-type="bibr" rid="R2">2</xref>). The other rapidly growing XBB.* and BF.7 sublineages are also highly resistant to anti-Spike mAbs(<xref ref-type="bibr" rid="R3">3</xref>). Polyclonal plasma from individuals who are both vaccinated and had COVID-19 (VaxCCP) has more than ten times the antibody levels capable of neutralizing pre-Omicron variants as well as Omicron variants BA.1 through BA.4/5(<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R5">5</xref>). Polyclonal COVID-19 convalescent plasma (CCP) has thousands of distinct antibody specificities of different isotypes, including many capable of SARS-CoV-2 neutralization. High-titer pre-Omicron CCP contains Omicron neutralizing activity despite being collected before variant appearance(<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R5">5</xref>).</p><p id="P6">Given that CCP remains a recommended therapy for IC(<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>), we systematically reviewed recent primary research for neutralization results against BQ.1.1 by plasma collected from vaccinated subjects with or without COVID-19 or after recent Omicron infection alone.</p></sec><sec id="S6" sec-type="results"><title>Results</title><p id="P7">Ten articles were included (<xref ref-type="fig" rid="F1">Figure 1</xref>) which contained virus neutralizations with WA-1, BQ.1.1, BA.4/5, BA.4.6, XBB.1 and BF.7, assessed with either live authentic SARS-CoV-2 or SARS-CoV-2 pseudovirus neutralization assays and represented data from 920 patients (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>). Qu <italic>et al</italic>. in the USA reported on Spring and Summer 2022 breakthrough infections with BA.1 and BA.4/5 in two sampled cohorts with predominantly unvaccinated individuals, as well as a third cohort of healthcare workers after a single monovalent booster vaccination in the Fall of 2021(<xref ref-type="bibr" rid="R8">8</xref>) (<xref ref-type="table" rid="T1">Table 1</xref>). Zou <italic>et al</italic>. in the USA in the Summer and Fall of 2022 sampled individuals who had already received 3 mRNA BNT162b2 vaccinations with or without previous COVID-19, both before and about 4 weeks after a 4<sup>th</sup> monovalent or bivalent vaccine booster vaccination(<xref ref-type="bibr" rid="R9">9</xref>). Miller <italic>et al</italic>. also in the USA sampled both before the 3<sup>rd</sup> vaccination dose and about 4 weeks after monovalent mRNA vaccination in the Fall of 2021, as well as with the 4th vaccine dose in the Summer or Fall of 2022, with either monovalent or bivalent booster vaccinations in Fall of 2022 in those with no documented COVID-19(<xref ref-type="bibr" rid="R10">10</xref>). Cao <italic>et al</italic>. in China investigated BQ.1.1 neutralizations from plasma of 4 cohorts after 3 doses of CoronaVac (Fall 2021) without COVID-19 or 2-12 weeks after BA.1, BA.2 and BA.5 infection(<xref ref-type="bibr" rid="R3">3</xref>). Planas <italic>et al</italic>. in France evaluated GMT<sub>50</sub>in plasma from individuals both 4 and 16 weeks after a third monovalent mRNA vaccine dose in the Fall of 2021 as well as 12 and 32 weeks after vaccine breakthrough BA.1/2 or BA.5 infection(<xref ref-type="bibr" rid="R11">11</xref>). Davis <italic>et al</italic> in the USA sampled after the 3<sup>rd</sup> mRNA vaccine monovalent dose in the Fall of 2021 and also after either a 4th monovalent mRNA dose or a bivalent (wild-type + BA.4/5) vaccine dose in the Summer and Fall of 2022(<xref ref-type="bibr" rid="R12">12</xref>). Kurhade <italic>et al</italic> in the USA also compared GMT<sub>50</sub>after the 4<sup>th</sup> monovalent vaccine dose or 3 mRNA doses with the 4<sup>th</sup> the bivalent dose without COVID-19 and also after bivalent boost with recent COVID-19(<xref ref-type="bibr" rid="R13">13</xref>). Wang <italic>et al</italic> in the USA compared GMT<sub>50</sub> after three vaccine doses, the 4<sup>th</sup> monovalent vaccine dose or 3 mRNA doses with the 4<sup>th</sup> the bivalent dose without COVID-19, and also after 2-3 vaccine doses and recent BA.2 breakthrough infection or 3-4 mRNA vaccine doses and recent BA.4/5 breakthrough infection(<xref ref-type="bibr" rid="R14">14</xref>). Ito et al in Japan compared breakthrough infections after BA.2 and BA.5 after 2-3 doses of mRNA vaccines in the Spring and Summer of 2022(<xref ref-type="bibr" rid="R15">15</xref>). Akerman et al in Australia characterized neutralizing antibodies in four groups 1) sampling one to three months after 3 doses of mRNA vaccines with an Omicron infection in 2022; 2) sampling 3 months after 4 doses of mRNA vaccine; 3) sampling 6 months after 3 doses of mRNA vaccine and 4) sampling 3-6 months after last vaccine in a larger cohort who had the original WA-1 infection in early 2020 as well as 3 more doses of mRNA vaccine(<xref ref-type="bibr" rid="R16">16</xref>).</p><p id="P8">These diverse cohorts were assembled into 3 groups, 1) plasma after both 2-4 vaccine doses and COVID-19 (VaxCCP); 2) plasma from subjects after administration of 3-4 vaccine doses (i.e. boosted), but either self-reported as COVID-19-<italic>na√Øve</italic> or anti-nucleocapsid negative; and 3) Omicron infection without vaccination (CCP) as well as participants sampled 6 to 11 months after previous vaccine dose and before the booster vaccination. Boosted VaxCCP neutralized BQ.1.1, XBB.1 and BF.7 with approximately 3 times the dilutional potency of the vaccine-only or 2-6 times CCP/pre-boost vaccination groups for all viral variants (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2</xref>). Importantly, while there was a 19-fold reduction in neutralization by boosted VaxCCP against BQ.1.1 compared to WA-1, more than 90% of the boosted VaxCCP samples neutralized BQ.1.1 as well as XBB.1 and BF.7 (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2c</xref>). Three cohorts within the boosted VaxCCP group were below at 90% neutralization with one sampled late, 8 months after BA.1/2 breakthrough infection(<xref ref-type="bibr" rid="R11">11</xref>) and the other two from a single study after BA.2 and BA.5 (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2 and 3</xref>). Except for the GMT (GMT<sub>50</sub>) against XBB.1 at 78, the other viral variant neutralizations were in the same range as pre-Alpha CCP neutralizing WA-1 (i.e., 311)(<xref ref-type="bibr" rid="R4">4</xref>). By comparison the large randomized clinical trial which effectively reduced outpatient COVID-19 progression to hospitalizations had a GMT<sub>50</sub> of 60 for WA-1 with pre-Alpha CCP(<xref ref-type="bibr" rid="R17">17</xref>). Boosted vaccinations at 3-4 doses without COVID-19, showed GM (GMT<sub>50</sub>) of 118 for BQ.1.1, with only 6 of 23 cohorts over 90% neutralizations, for 79% overall (i.e. 326 of 414 individuals). Four separate studies(<xref ref-type="bibr" rid="R8">8</xref>),(<xref ref-type="bibr" rid="R13">13</xref>),(<xref ref-type="bibr" rid="R12">12</xref>),(<xref ref-type="bibr" rid="R10">10</xref>) characterized BQ.1.1 virus neutralizations with plasma after the new bivalent (wild-type + BA.4/5) mRNA vaccine booster in the Fall of 2022, with 88% (103 of 117 samples) neutralization activity within 4 weeks of bivalent booster (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>).</p><p id="P9">Many studies performed virus neutralizations on samples drawn before the 3<sup>rd</sup> or 4<sup>th</sup> vaccine dose which were 6 to 11 months after last vaccine dose. The GM (GMT<sub>50</sub>)‚Äôs for BQ.1.1 and BA.2.75 were about 6 times reduced compared to VaxCCP even though the fold reductions were similar (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>). In agreement with lower GMT<sub>50</sub> for neutralizations was the low percent neutralizing BQ.1.1 (63%), XBB.1 (50%), and BF.7 (75%) at 6 to 11 months after vaccination (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>).</p><p id="P10">Five studies used the lentiviral pseudovirus assays, with diverse Spike proteins cloned in, while the other four were live virus assays using different cell types (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>). Notably, Planas <italic>et al</italic> employed the IGROV-1 cell type for better growth of Omicron sublineages(<xref ref-type="bibr" rid="R11">11</xref>). While the single study fold reductions (FR) and percent neutralizations normalize the results between studies, the GMT<sub>50</sub> can vary between studies even amongst the live authentic viral neutralization studies (e.g., mNeonGreen‚Ñ¢ reporter assays versus cytopathic effects)(<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R13">13</xref>). We sorted the live authentic viral neutralizations from the pseudoviral neutralizations, plotting also the minimum and maximums (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figures 1-3</xref>). In general, the live authentic SARS-CoV-2 neutralization assays for VaxCCP appeared to have similar antibody neutralization levels, with the single study by Cao et al(<xref ref-type="bibr" rid="R3">3</xref>) employing lentiviral pseudovirus with lower dilutional titers. In contrast, the GMT<sub>50</sub> achieved with pseudoviral assays in the boosted vaccinations without COVID-19 appeared slightly higher than the ones achieved with authentic virus.</p></sec><sec id="S7" sec-type="discussion"><title>Discussion</title><p id="P11">The FDA deemed CCP safe and effective for both immunocompetent and IC COVID-19 outpatients(<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R18">18</xref>), and further extended its authorized use in the IC patient population in December 2021(<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R18">18</xref>), at a time when oral antiviral therapy promised a no transfusion outpatient solution and many anti-Spike mAbs were still effective.</p><p id="P12">Up until the present, CCP remained a backup bridge for IC patients, durable against the changing variants and as a salvage therapy in seronegative IC patients. With the recent advent of Omicron XBB.* and BQ.1.* defeating the remaining anti-Spike mAbs, boosted VaxCCP, recently collected within the last 6 months of either a vaccine dose or SARS-CoV-2 is likely to be the only viable remaining passive antibody therapy in the 2022-23 Winter for IC patients who have failed to make antibodies after vaccination and still require B-cell depleting drugs or immunosuppressive therapy. In a literature review of CCP from diverse VOC waves as well as boosted vaccinees and VaxCCP up to BA-1, VaxCCP showed higher neutralization titers against Omicron at levels above 300 dilutional GMT<sub>50</sub><sup>4</sup>.</p><p id="P13">The accelerated evolution of SARS-CoV-2 VOCs has created the problem that the pharmaceutical development of additional mAbs is not worth the effort and cost given their expected short useful clinical life expectancy, so the anti-Spike mAb pipeline has remained stuck in 2022. High levels of antibodies in donor plasma from both boosted vaccinations and COVID-19 convalescent plasma (VaxCCP) neutralizing more than 93% of BQ.1.1and BF.7, with XBB.1 at 89%. Recently collected plasma within a 6 months window from those boosted vaccinees without prior documented COVID-19 had a 20-30% reduction in neutralization percent for BQ.1.1and XBB.1 with 10% reduction for the others and a third of the GM (GMT<sub>50</sub>) neutralizing antibody levels compared to VaxCCP. In those vaccinated with last dose more than 6 months prior to sample collection, both the neutralization percent and neutralizing antibody titers fell further, compared to the recently boosted VaxCCP group. Four studies (Planas(<xref ref-type="bibr" rid="R11">11</xref>), Zou(<xref ref-type="bibr" rid="R9">9</xref>), Cao(<xref ref-type="bibr" rid="R3">3</xref>) and Kurhade(<xref ref-type="bibr" rid="R13">13</xref>)) had directly comparative cohorts in the three groups which increases the robustness reduction in neutralizations with the vaccine only or more than 6 months to last vaccine or infection event compared to VaxCCP. The main limitation of our systematic review is the small number of studies reporting virus neutralization with BQ.1.1 with most available as pre-preprints without peer-review yet. However, we note that peer-review itself does not change GMT<sub>50</sub> or neutralization numbers and the authors of these papers have considerable expertise in the topic.</p><p id="P14">Boosted VaxCCP has full potential to replace anti-Spike mAbs for passive antibody therapy of IC patients against recent Omicron sublineages, in the meanwhile polyclonal IgG formulations can be manufactured. VaxCCP qualification in the real-world will likely remain constrained on high-throughput serology, whose correlation with GMT<sub>50</sub> is not perfect(<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R20">20</xref>). Nevertheless, the very high prevalence (93%) of Omicron-neutralizing antibodies and the high GM (GMT<sub>50</sub>) in recently boosted VaxCCP reassure about its potency, and further confirm that exact donor-recipient VOC matching is dispensable. Overall, our findings urge WHO to revise its guidelines and recommend boosted VaxCCP for therapy of COVID-19 in IC patients.</p><sec id="S8"><title>Search strategy and selection criteria</title><p id="P15">On November 19, 2022 we initially searched PubMed, medRxiv and bioRxiv for manuscripts reporting BQ.1.1 neutralization, using English language as a restriction. Search of bioRxiv with same keywords now yields 17 records of which only 10 contained plasma viral neutralization data. Search of medRxiv produced 3 records which did not have BQ.1.1 neutralizations. PubMed retrieved 3 entries using (‚ÄúBQ.1.1‚Äù) and (‚Äúneutralization‚Äù), one of which was focused on anti-Spike mAb alone(<xref ref-type="bibr" rid="R2">2</xref>) and the other 2 were duplicates from bioRxiv(<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R12">12</xref>). Articles underwent evaluation for data extraction by two assessors (DS and DF) with disagreements resolved by third assessor (AC). Articles lacking plasma BQ.1.1 virus neutralizations were excluded. The process of study selection is represented in the PRISMA flow diagram (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><p id="P16">The type of viral assay (live or pseudovirus), time interval to blood sample, GMT<sub>50</sub>, minimum and maximum neutralizing 50% dilutional titer for WA-1 (pre-Alpha wild-type) and Omicron sublineages BQ.1.1, BA.4/5, BA.4.6, BA.2.75, XBB.1 and BF.7 and number out of total that neutralized Omicron were abstracted from study text, graphs and tables. Two studies (Wang(<xref ref-type="bibr" rid="R14">14</xref>) and Qu(<xref ref-type="bibr" rid="R8">8</xref>)) reported BQ.1 and those were separate cohorts in addition to BQ.1.1. Prism v. 9.4 (GraphPad Software, San Diego, CA, USA) was used for data analysis. While all manuscripts included neutralization data against WA-1, BQ.1.1, BA.4/5 and BA.2.75, only a subset of manuscripts included neutralization data for BA.4.6, XBB.1 and BF.7 which were assembled for relevance to present circulating variants. Historic early Omicron partial neutralization data on variants like BA.1 or BA.2 were excluded because of the full set data with BA.4/5 and BA.2.75.</p><p id="P17">Statistical significance between log<sub>10</sub> transformed GMT<sub>50</sub> was investigated using Tukey‚Äôs test. The multiple comparison test was a two-way ANOVA with Alpha 0.05 on log transformed GMT<sub>50</sub>. The log normal test was performed on WA-1, BQ.1.1, BA.4/5, BA.4.6, XBB.1 and BF.7 virus GMT<sub>50</sub>. Two studies(<xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R11">11</xref>) reported the median titer rather than the GMT<sub>50</sub>. Compiled data abstracted from the published studies is available in the supplementary dataset.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Figures and Tables</label><media xlink:href="EMS157837-supplement-Supplementary_Figures_and_Tables.pdf" mimetype="application" mime-subtype="pdf" id="d95aAdDbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S9"><title>Funding</title><p>This study was supported by the U.S. Department of Defense‚Äôs Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (DS), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases 3R01AI152078-01S1 (DS, AC), NIH National Center for Advancing Translational Sciences U24TR001609-S3 and UL1TR003098.</p><sec id="S10"><title>Role of the funding source</title><p>The study sponsors did not contribute to the study design; the collection, analysis, and interpretation of data; manuscript preparation, and the decision to submit the paper for publication.</p><p>The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense. The data and opinions presented do not reflect the view of the U.S. government.</p></sec></ack><sec id="S11" sec-type="data-availability"><title>Data availability statement</title><p id="P18">all the data used for this manuscript are available in the Supplementary Dataset file.</p></sec><glossary><title>Abbreviations</title><def-list><def-item><term>VOC</term><def><p>variant of concern;</p></def></def-item><def-item><term>VaxCCP</term><def><p>plasma from both vaccinated and COVID-19 convalescent subjects</p></def></def-item></def-list></glossary><fn-group><fn id="FN1" fn-type="con"><p id="P19"><bold>Author contributions:</bold> DJS: data extraction, table curation and design, and writing original draft; D.F.: conceptualization, data access and verification and manuscript revision; M.F. data access and verification and manuscript revision; JWS data access and verification and manuscript revision, MJJ and AC manuscript revision.</p></fn><fn id="FN2" fn-type="conflict"><p id="P20"><bold>Conflict of interest disclosure</bold></p><p id="P21">DJS reports AliquantumRx Founder and Board member with stock options (macrolide for malaria), Hemex Health malaria diagnostics consulting and royalties for malaria diagnostic test control standards to Alere- all outside of submitted work. AC reports being part of the scientific advisory board of SabTherapeutics and has received personal fees from Ortho Diagnostics, outside of the submitted work. All other authors report no relevant disclosures.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senefeld</surname><given-names>JW</given-names></name><name><surname>Franchini</surname><given-names>M</given-names></name><name><surname>Mengoli</surname><given-names>C</given-names></name><name><surname>Cruciani</surname><given-names>M</given-names></name><name><surname>Zani</surname><given-names>M</given-names></name><name><surname>Gorman</surname><given-names>EK</given-names></name><etal/></person-group><article-title>COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review</article-title><source>medRxiv</source><year>2022</year><elocation-id>2022.08.03.22278359</elocation-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>P</given-names></name><name><surname>Kempf</surname><given-names>A</given-names></name><name><surname>Nehlmeier</surname><given-names>I</given-names></name><name><surname>Schulz</surname><given-names>SR</given-names></name><name><surname>Jack</surname><given-names>HM</given-names></name><name><surname>Pohlmann</surname><given-names>S</given-names></name><etal/></person-group><article-title>Omicron sublineage BQ.1.1 resistance to monoclonal antibodies</article-title><source>Lancet Infect Dis</source><year>2022</year><month>Nov</month><day>18</day><comment>Epub 2022/11/22</comment><pub-id pub-id-type="pmcid">PMC9707647</pub-id><pub-id pub-id-type="pmid">36410372</pub-id><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00733-2</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Jian</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Yisimayi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.09.15.507787</elocation-id><pub-id pub-id-type="pmid">36535326</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>DJ</given-names></name><name><surname>Franchini</surname><given-names>M</given-names></name><name><surname>Joyner</surname><given-names>MJ</given-names></name><name><surname>Casadevall</surname><given-names>A</given-names></name><name><surname>Focosi</surname><given-names>D</given-names></name></person-group><article-title>Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources</article-title><source>Nature Communications</source><year>2022</year><volume>13</volume><issue>1</issue><elocation-id>6478</elocation-id><comment>2022/10/29</comment><pub-id pub-id-type="pmcid">PMC9617541</pub-id><pub-id pub-id-type="pmid">36309490</pub-id><pub-id pub-id-type="doi">10.1038/s41467-022-33864-y</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>EJ</given-names></name><name><surname>Laeyendecker</surname><given-names>O</given-names></name><name><surname>Eby</surname><given-names>YJ</given-names></name><name><surname>Tobian</surname><given-names>AA</given-names></name><name><surname>Caturegli</surname><given-names>P</given-names></name><etal/></person-group><article-title>Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern</article-title><source>Blood Adv</source><year>2022</year><elocation-id>2022.03.01.22271662</elocation-id><pub-id pub-id-type="pmcid">PMC9023079</pub-id><pub-id pub-id-type="pmid">35443020</pub-id><pub-id pub-id-type="doi">10.1182/bloodadvances.2022007410</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hinton</surname><given-names>DM</given-names></name></person-group><chapter-title>Convalescent Plasma EUA Letter of Authorization 06032021</chapter-title><person-group person-group-type="editor"><collab>FDA</collab></person-group><source>FDA in brief: FDA</source><year>2021</year></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Shaughnessy</surname><given-names>JA</given-names></name></person-group><article-title>Convalescent Plasma EUA Letter of Authorization 12282021</article-title><source>FDA website</source><year>2021</year></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>JP</given-names></name><name><surname>Faraone</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>Y-M</given-names></name><name><surname>Carlin</surname><given-names>C</given-names></name><name><surname>Anghelina</surname><given-names>M</given-names></name><etal/></person-group><article-title>Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.10.19.512891</elocation-id><pub-id pub-id-type="pmcid">PMC9678813</pub-id><pub-id pub-id-type="pmid">36476380</pub-id><pub-id pub-id-type="doi">10.1016/j.chom.2022.11.012</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Kurhade</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Tompkins</surname><given-names>K</given-names></name><name><surname>Cutler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.11.17.516898</elocation-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Hachmann</surname><given-names>NP</given-names></name><name><surname>Collier</surname><given-names>A-rY</given-names></name><name><surname>Lasrado</surname><given-names>N</given-names></name><name><surname>Mazurek</surname><given-names>CR</given-names></name><name><surname>Patio</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.11.01.514722</elocation-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planas</surname><given-names>D</given-names></name><name><surname>Bruel</surname><given-names>T</given-names></name><name><surname>Staropoli</surname><given-names>I</given-names></name><name><surname>Guivel-Benhassine</surname><given-names>F</given-names></name><name><surname>Porrot</surname><given-names>F</given-names></name><name><surname>Maes</surname><given-names>P</given-names></name><etal/></person-group><article-title>Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.11.17.516888</elocation-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis-Gardner</surname><given-names>ME</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Wali</surname><given-names>B</given-names></name><name><surname>Samaha</surname><given-names>H</given-names></name><name><surname>Solis</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><etal/></person-group><article-title>mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.10.31.514636</elocation-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurhade</surname><given-names>C</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>HC</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><etal/></person-group><article-title>Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.10.31.514580</elocation-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Iketani</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.11.23.517532</elocation-id><pub-id pub-id-type="pmcid">PMC9747694</pub-id><pub-id pub-id-type="pmid">36580913</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2022.12.018</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Uriu</surname><given-names>K</given-names></name><name><surname>Itakura</surname><given-names>Y</given-names></name><name><surname>Zahradnik</surname><given-names>J</given-names></name><name><surname>Deguchi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.12.05.519085</elocation-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akerman</surname><given-names>A</given-names></name><name><surname>Milogiannakis</surname><given-names>V</given-names></name><name><surname>Jean</surname><given-names>T</given-names></name><name><surname>Esneu</surname><given-names>C</given-names></name><name><surname>Silva</surname><given-names>MR</given-names></name><name><surname>Ison</surname><given-names>T</given-names></name><etal/></person-group><article-title>Emergence and antibody evasion of BQ and BA.2.75 SARS-CoV-2 sublineages in the face of maturing antibody breadth at the population level</article-title><source>medRxiv</source><year>2022</year><elocation-id>2022.12.06.22283000</elocation-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>DJ</given-names></name><name><surname>Gebo</surname><given-names>KA</given-names></name><name><surname>Shoham</surname><given-names>S</given-names></name><name><surname>Bloch</surname><given-names>EM</given-names></name><name><surname>Lau</surname><given-names>B</given-names></name><name><surname>Shenoy</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Early Outpatient Treatment for Covid-19 with Convalescent Plasma</article-title><source>N Engl J Med</source><year>2022</year><month>Mar</month><day>30</day><comment>PubMed. Pubmed Central. Epub 2022/03/31</comment><pub-id pub-id-type="pmcid">PMC9006786</pub-id><pub-id pub-id-type="pmid">35353960</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2119657</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>C</given-names></name></person-group><chapter-title>EUA 26382 COVID-19 Convalescent Plasma</chapter-title><person-group person-group-type="editor"><collab>OBRR</collab></person-group><year>2021</year><publisher-name>FDA</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/155159/download">https://www.fda.gov/media/155159/download</ext-link></comment></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>M</given-names></name><name><surname>Grebe</surname><given-names>E</given-names></name><name><surname>Sulaeman</surname><given-names>H</given-names></name><name><surname>Di Germanio</surname><given-names>C</given-names></name><name><surname>Dave</surname><given-names>H</given-names></name><name><surname>Kelly</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications</article-title><source>Emerg Infect Dis</source><year>2022</year><month>Mar</month><volume>28</volume><issue>3</issue><fpage>672</fpage><lpage>83</lpage><comment>Epub 2022/02/25</comment><pub-id pub-id-type="pmcid">PMC8888213</pub-id><pub-id pub-id-type="pmid">35202525</pub-id><pub-id pub-id-type="doi">10.3201/eid2803.211885</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>EU</given-names></name><name><surname>Bloch</surname><given-names>EM</given-names></name><name><surname>Clarke</surname><given-names>W</given-names></name><name><surname>Hsieh</surname><given-names>YH</given-names></name><name><surname>Boon</surname><given-names>D</given-names></name><name><surname>Eby</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers</article-title><source>J Clin Microbiol</source><year>2021</year><month>Jan</month><day>21</day><volume>59</volume><issue>2</issue><comment>Epub 2020/11/04</comment><pub-id pub-id-type="pmcid">PMC8111143</pub-id><pub-id pub-id-type="pmid">33139419</pub-id><pub-id pub-id-type="doi">10.1128/JCM.02257-20</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>PRISMA flowchart for the current study. Number of records identified from various sources, excluded by manual screening, found eligible and included according to subgroup analyses.</p></caption><graphic xlink:href="EMS157837-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Neutralizing GMT (GMT<sub>50</sub>) against WA-1, BQ.1.1, BA.4/5, BA.4.6, BA.2.75, XBB, BF.7.</title><p>A) post boosted vaccinations and COVID-19 and B) boosted vaccinated plasma without COVID-19. Geometric standard deviation for error bars, fold reduction (FR) below data, and number of studies above x-axis. Geomeans statistically significant in difference by multiple comparison in Tukey‚Äôs test are indicated. C) The percent of total samples within a study which neutralized Omicron BQ.1.1 graphed in increasing percentages on left y axis with the total number of samples tested on the right y axis.</p></caption><graphic xlink:href="EMS157837-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Geometric mean neutralizing titers (GMT<sub>50</sub>) against WA-1, BQ.1.1, BA.4/5, BA.4.6, BA.2.75, XBB, BF.7</title><p>A) plasma Omicron infection alone or pre-boosted-6 to 11 months after last vaccine dose sampled in 2021 or 2022. Geometric standard deviation for error bars, fold reduction (FR) above data, and number of studies above x-axis. GM (GMT<sub>50</sub>) statistically significant in difference by multiple comparison in Tukey‚Äôs test are indicated. B). The percent of total samples within a study which neutralized Omicron BQ.1.1 graphed in increasing percentages on left y-axis with the total number of samples tested on the right y-axis.</p></caption><graphic xlink:href="EMS157837-f003"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Synopsis of included studies, reporting plasma sources, epoch of sampling, region, time since vaccination/infection to plasma sampling, and sample size. The cohorts were split into three groups-1) boosted vaccinations and recent COVID-19 (VaxCCP), 2) boosted vaccines only without documented COVID-19 (Vac only) and 3) infection alone or pre-boosted sampling before 3<sup>rd</sup> or 4<sup>th</sup> vaccine dose (Infection only or pre-boost)</p></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="bottom">Study</th><th align="center" valign="bottom">Vaccine and COVID-19 history at sample time</th><th align="center" valign="bottom">Group</th><th align="center" valign="bottom">Time period of plasma sampling</th><th align="center" valign="bottom">Geography</th><th align="center" valign="bottom">Sampling time mean or median (min-max)</th><th align="center" valign="bottom">Sample number</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cao(3)</td><td align="left" valign="bottom">3xCorVac+BA.1 inf</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Spring 2022</td><td align="left" valign="bottom">China</td><td align="left" valign="bottom">5-7 weeks post hosp admit (42 weeks avg)</td><td align="left" valign="bottom">50</td></tr><tr><td align="left" valign="bottom">Cao(3)</td><td align="left" valign="bottom">3xCorVac +BA.2 inf</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Summer 2022</td><td align="left" valign="bottom">China</td><td align="left" valign="bottom">3-11 weeks post hosp admit (8 weeks mean)</td><td align="left" valign="bottom">39</td></tr><tr><td align="left" valign="bottom">Cao(3)</td><td align="left" valign="bottom">3xCorVac +BA.5 inf</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">China</td><td align="left" valign="bottom">2-11 weeks (mean 5 weeks)</td><td align="left" valign="bottom">36</td></tr><tr><td align="left" valign="bottom">Zou(9)</td><td align="left" valign="bottom">4xBNT162b2+BTI</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">4 weeks post dose</td><td align="left" valign="bottom">20</td></tr><tr><td align="left" valign="bottom">Planas(11)</td><td align="left" valign="bottom">mRNAvacx3+BA.1/2 inf</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Spring/Fall 2022</td><td align="left" valign="bottom">France</td><td align="left" valign="bottom">32 weeks post BTI BA.1/2</td><td align="left" valign="bottom">13</td></tr><tr><td align="left" valign="bottom">Wang(14)</td><td align="left" valign="bottom">2-3xmRNAvac+BA.2 BTI</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Spring/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">2-23 weeks (mean 6 wk (3over 90 days))</td><td align="left" valign="bottom">14</td></tr><tr><td align="left" valign="bottom">Wang(14)</td><td align="left" valign="bottom">3-4xmRNAvac+BA.4/5 BTI</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">2-8 weeks (mean 4 weeks)</td><td align="left" valign="bottom">20</td></tr><tr><td align="left" valign="bottom">Kurhade(13)</td><td align="left" valign="bottom">3xmRNAvac+bivalent+BTI</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">4 weeks post with infection history</td><td align="left" valign="bottom">23</td></tr><tr><td align="left" valign="bottom">Ito(15)</td><td align="left" valign="bottom">2-3xmRNAvac+BA.2 BTI</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Spring 2022</td><td align="left" valign="bottom">Japan</td><td align="left" valign="bottom">2-8 weeks</td><td align="left" valign="bottom">14</td></tr><tr><td align="left" valign="bottom">Ito(15)</td><td align="left" valign="bottom">2-3xmRNAvac+BA.5 BTI</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Summer 2022</td><td align="left" valign="bottom">Japan</td><td align="left" valign="bottom">2-3 weeks</td><td align="left" valign="bottom">20</td></tr><tr><td align="left" valign="bottom">Zou(9)</td><td align="left" valign="bottom">3xBNT162b2+bivalent+BTI</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">4 weeks post dose</td><td align="left" valign="bottom">19</td></tr><tr><td align="left" valign="bottom">Akerman(16)</td><td align="left" valign="bottom">3xmRNA +bivalent</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Fall 2022</td><td align="left" valign="bottom">Australia</td><td align="left" valign="bottom">4-12 weeks post BTI</td><td align="left" valign="bottom">29</td></tr><tr><td align="left" valign="bottom">Planas(11)</td><td align="left" valign="bottom">3xmRNAvac+BA.1/2 inf</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Spring/Fall 2022</td><td align="left" valign="bottom">France</td><td align="left" valign="bottom">12 weeks post BTI BA.1/2</td><td align="left" valign="bottom">16</td></tr><tr><td align="left" valign="bottom">Planas(11)</td><td align="left" valign="bottom">3xmRNAvac+BA.5 inf</td><td align="left" valign="bottom">VaxCCP</td><td align="left" valign="bottom">Fall 2022</td><td align="left" valign="bottom">France</td><td align="left" valign="bottom">8 weeks post BTI BA.5</td><td align="left" valign="bottom">15</td></tr><tr><td align="left" valign="bottom">Davis(12)</td><td align="left" valign="bottom">3xmRNAvac</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Fall 2021</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">1-4 weeks post boost</td><td align="left" valign="bottom">12</td></tr><tr><td align="left" valign="bottom">Kurhade(13)</td><td align="left" valign="bottom">4xmRNAvac</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Summer 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">4-12 weeks</td><td align="left" valign="bottom">25</td></tr><tr><td align="left" valign="bottom">Cao(3)</td><td align="left" valign="bottom">3xCorVac</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Fall 2021</td><td align="left" valign="bottom">China</td><td align="left" valign="bottom">4 weeks</td><td align="left" valign="bottom">40</td></tr><tr><td align="left" valign="bottom">Zou(9)</td><td align="left" valign="bottom">4xBNT162b2</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">4 weeks post dose</td><td align="left" valign="bottom">20</td></tr><tr><td align="left" valign="bottom">Planas(11)</td><td align="left" valign="bottom">3xmRNAvac</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Winter 2021/2022</td><td align="left" valign="bottom">France</td><td align="left" valign="bottom">16 weeks post 3rd dose</td><td align="left" valign="bottom">10</td></tr><tr><td align="left" valign="bottom">Wang(14)</td><td align="left" valign="bottom">3xmRNAvac</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Fall 2021</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">2-12 weeks (mean 5 weeks)</td><td align="left" valign="bottom">14</td></tr><tr><td align="left" valign="bottom">Wang(14)</td><td align="left" valign="bottom">3xmRNAvac+monovalent</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">3-4 weeks</td><td align="left" valign="bottom">19</td></tr><tr><td align="left" valign="bottom">Wang(14)</td><td align="left" valign="bottom">3xmRNAvac+bivalent</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">3-4 weeks</td><td align="left" valign="bottom">21</td></tr><tr><td align="left" valign="bottom">Davis(12)</td><td align="left" valign="bottom">3xmRNAvac+monovalent</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">10-15 weeks post boost</td><td align="left" valign="bottom">12</td></tr><tr><td align="left" valign="bottom">Akerman(16)</td><td align="left" valign="bottom">4xmRNA</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Fall 2022</td><td align="left" valign="bottom">Australia</td><td align="left" valign="bottom">12 weeks</td><td align="left" valign="bottom">23</td></tr><tr><td align="left" valign="bottom">Akerman(16)</td><td align="left" valign="bottom">3xmRNAvac after 2020 WA-1</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">Australia</td><td align="left" valign="bottom">3-6 months</td><td align="left" valign="bottom">47</td></tr><tr><td align="left" valign="bottom">Kurhade(13)</td><td align="left" valign="bottom">3xmRNAvac+bivalent</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">4 weeks post</td><td align="left" valign="bottom">29</td></tr><tr><td align="left" valign="bottom">Davis(12)</td><td align="left" valign="bottom">3xmRNAvac+bivalent</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">2-6 weeks post booster (8 no vacc. 10 no infection)</td><td align="left" valign="bottom">12</td></tr><tr><td align="left" valign="bottom">Qu(8)</td><td align="left" valign="bottom">3xmRNAvac</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Fall 2021</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">2-13 weeks</td><td align="left" valign="bottom">15</td></tr><tr><td align="left" valign="bottom">Zou(9)</td><td align="left" valign="bottom">3xBNT162b2+bivalent</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">4 week post dose</td><td align="left" valign="bottom">18</td></tr><tr><td align="left" valign="bottom">Planas(11)</td><td align="left" valign="bottom">3xmRNAvac</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Fall/Winter 2021</td><td align="left" valign="bottom">France</td><td align="left" valign="bottom">4 weeks post 3rd dose</td><td align="left" valign="bottom">18</td></tr><tr><td align="left" valign="bottom">Miller(10)</td><td align="left" valign="bottom">3xBNT162b2</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Fall 2021</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">2-4 weeks</td><td align="left" valign="bottom">16</td></tr><tr><td align="left" valign="bottom">Miller(10)</td><td align="left" valign="bottom">3xmRNA+monovalent</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Spring/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">2-9 weeks</td><td align="left" valign="bottom">18</td></tr><tr><td align="left" valign="bottom">Miller(10)</td><td align="left" valign="bottom">3xmRNA +bivalent</td><td align="left" valign="bottom">Vac only</td><td align="left" valign="bottom">Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">2-3 weeks</td><td align="left" valign="bottom">15</td></tr><tr><td align="left" valign="bottom">Qu(8)</td><td align="left" valign="bottom">BA.4/5 inf (17-unvac)</td><td align="left" valign="bottom">Inf only</td><td align="left" valign="bottom">Summer 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">not stated</td><td align="left" valign="bottom">20</td></tr><tr><td align="left" valign="bottom">Qu(8)</td><td align="left" valign="bottom">Hosp BA.1 (6-unvac;5- 2xmRNAvac)</td><td align="left" valign="bottom">Inf only</td><td align="left" valign="bottom">Spring 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">1 week post hospitalization</td><td align="left" valign="bottom">15</td></tr><tr><td align="left" valign="bottom">Zou(9)</td><td align="left" valign="bottom">3xBNT162b2+BTI</td><td align="left" valign="bottom">preboost with BNT162b</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">preboost with BNT162b (6-11 months post last dose)</td><td align="left" valign="bottom">20</td></tr><tr><td align="left" valign="bottom">Zou(9)</td><td align="left" valign="bottom">3xBNT162b2 +BTI</td><td align="left" valign="bottom">preboost with bivalent</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">preboost with bivalent (611 months post last dose)</td><td align="left" valign="bottom">19</td></tr><tr><td align="left" valign="bottom">Zou(9)</td><td align="left" valign="bottom">3xBNT162b2</td><td align="left" valign="bottom">preboost with bivalent</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">preboost with bivalent (611 months post last dose)</td><td align="left" valign="bottom">18</td></tr><tr><td align="left" valign="bottom">Zou(9)</td><td align="left" valign="bottom">3xBNT162b2</td><td align="left" valign="bottom">preboost with BNT162 b</td><td align="left" valign="bottom">Summer/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">preboost with BNT162b (6-11 months post last dose)</td><td align="left" valign="bottom">20</td></tr><tr><td align="left" valign="bottom">Akerman(16)</td><td align="left" valign="bottom">3xmRNA</td><td align="left" valign="bottom">Preboost</td><td align="left" valign="bottom">Fall 2022</td><td align="left" valign="bottom">Australia</td><td align="left" valign="bottom">preboost (6 months)</td><td align="left" valign="bottom">47</td></tr><tr><td align="left" valign="bottom">Miller(10)</td><td align="left" valign="bottom">2xBNT162b2</td><td align="left" valign="bottom">preboost with BNT162 b</td><td align="left" valign="bottom">Fall 2021</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">preboost (6-11 months post last dose)</td><td align="left" valign="bottom">16</td></tr><tr><td align="left" valign="bottom">Miller(10)</td><td align="left" valign="bottom">3xmRNA</td><td align="left" valign="bottom">preboost with bivalent</td><td align="left" valign="bottom">Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">preboost with bivalent (611 months post last dose)</td><td align="left" valign="bottom">15</td></tr><tr><td align="left" valign="bottom">Miller(10)</td><td align="left" valign="bottom">3xmRNA</td><td align="left" valign="bottom">preboost with monovalent</td><td align="left" valign="bottom">Spring/Fall 2022</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">preboost with monovalent (6-11 months post last dose)</td><td align="left" valign="bottom">18</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><title>GM (GMT<sub>50</sub>) of plasma from three different sources against recent Omicron sublineages.</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle">Neutralization virus</th><th align="center" valign="middle">WA-1</th><th align="center" valign="middle">BQ.1.1</th><th align="center" valign="middle">BA.4/5</th><th align="center" valign="middle">BA.4.6</th><th align="center" valign="middle">BA.2.75</th><th align="center" valign="middle">XBB.1</th><th align="center" valign="middle">BF.7</th></tr></thead><tbody><tr><td align="left" valign="middle"><bold>Post COVID-19/vaccine (study cohorts)</bold></td><td align="right" valign="middle">12</td><td align="right" valign="middle">16</td><td align="right" valign="middle">14</td><td align="right" valign="middle">7</td><td align="right" valign="middle">9</td><td align="right" valign="middle">9</td><td align="right" valign="middle">4</td></tr><tr><td align="left" valign="middle">GM (GMT<sub>50</sub>)</td><td align="right" valign="middle">5876<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="right" valign="middle">314</td><td align="right" valign="middle">987</td><td align="right" valign="middle">346</td><td align="right" valign="middle">303</td><td align="right" valign="middle">78</td><td align="right" valign="middle">204</td></tr><tr><td align="left" valign="middle">Fold reduction from WA-1</td><td align="right" valign="middle">ref</td><td align="right" valign="middle">19</td><td align="right" valign="middle">6</td><td align="right" valign="middle">17</td><td align="right" valign="middle">19</td><td align="right" valign="middle">75</td><td align="right" valign="middle">32</td></tr><tr><td align="left" valign="middle">Samples tested</td><td align="right" valign="middle">294</td><td align="right" valign="middle">237<xref ref-type="table-fn" rid="TFN2">**</xref></td><td align="right" valign="middle">328</td><td align="right" valign="middle">135</td><td align="right" valign="middle">231</td><td align="right" valign="middle">125</td><td align="right" valign="middle">148</td></tr><tr><td align="left" valign="middle">Samples neutralizing</td><td align="right" valign="middle">285</td><td align="right" valign="middle">221</td><td align="right" valign="middle">326</td><td align="right" valign="middle">135</td><td align="right" valign="middle">230</td><td align="right" valign="middle">111</td><td align="right" valign="middle">146</td></tr><tr><td align="left" valign="middle">Percent neutralizing</td><td align="right" valign="middle">97</td><td align="right" valign="middle">93</td><td align="right" valign="middle">99</td><td align="right" valign="middle">100</td><td align="right" valign="middle">100</td><td align="right" valign="middle">89</td><td align="right" valign="middle">99</td></tr><tr><td align="left" valign="middle"><bold>Boosted vaccine (study cohorts)</bold></td><td align="right" valign="middle">19</td><td align="right" valign="middle">23</td><td align="right" valign="middle">19</td><td align="right" valign="middle">10</td><td align="right" valign="middle">14</td><td align="right" valign="middle">10</td><td align="right" valign="middle">7</td></tr><tr><td align="left" valign="middle">GM (GMT<sub>50</sub>)</td><td align="right" valign="middle">3766</td><td align="right" valign="middle">118</td><td align="right" valign="middle">346</td><td align="right" valign="middle">126</td><td align="right" valign="middle">107</td><td align="right" valign="middle">52</td><td align="right" valign="middle">357</td></tr><tr><td align="left" valign="middle">Fold reduction from WA-1</td><td align="right" valign="middle">ref</td><td align="right" valign="middle">32</td><td align="right" valign="middle">11</td><td align="right" valign="middle">30</td><td align="right" valign="middle">35</td><td align="right" valign="middle">72</td><td align="right" valign="middle">12</td></tr><tr><td align="left" valign="middle">Samples tested</td><td align="right" valign="middle">384</td><td align="right" valign="middle">414</td><td align="right" valign="middle">384</td><td align="right" valign="middle">206</td><td align="right" valign="middle">261</td><td align="right" valign="middle">217</td><td align="right" valign="middle">158</td></tr><tr><td align="left" valign="middle">Samples neutralizing</td><td align="right" valign="middle">383</td><td align="right" valign="middle">326</td><td align="right" valign="middle">363</td><td align="right" valign="middle">191</td><td align="right" valign="middle">231</td><td align="right" valign="middle">125</td><td align="right" valign="middle">149</td></tr><tr><td align="left" valign="middle">Percent neutralizing</td><td align="right" valign="middle">100</td><td align="right" valign="middle">79</td><td align="right" valign="middle">95</td><td align="right" valign="middle">93</td><td align="right" valign="middle">89</td><td align="right" valign="middle">58</td><td align="right" valign="middle">94</td></tr><tr><td align="left" valign="middle"><bold>Infection only or preboosted vaccine (study cohorts)</bold></td><td align="right" valign="middle">10</td><td align="right" valign="middle">12</td><td align="right" valign="middle">10</td><td align="right" valign="middle">7</td><td align="right" valign="middle">9</td><td align="right" valign="middle">5</td><td align="right" valign="middle">5</td></tr><tr><td align="left" valign="middle">GM (GMT<sub>50</sub>)</td><td align="right" valign="middle">870</td><td align="right" valign="middle">47</td><td align="right" valign="middle">96</td><td align="right" valign="middle">103</td><td align="right" valign="middle">57</td><td align="right" valign="middle">23</td><td align="right" valign="middle">110</td></tr><tr><td align="left" valign="middle">Fold reduction from WA-1</td><td align="right" valign="middle">ref</td><td align="right" valign="middle">19</td><td align="right" valign="middle">9</td><td align="right" valign="middle">8</td><td align="right" valign="middle">15</td><td align="right" valign="middle">38</td><td align="right" valign="middle">9</td></tr><tr><td align="left" valign="middle">Samples tested</td><td align="right" valign="middle">184</td><td align="right" valign="middle">220</td><td align="right" valign="middle">184</td><td align="right" valign="middle">136</td><td align="right" valign="middle">162</td><td align="right" valign="middle">101</td><td align="right" valign="middle">84</td></tr><tr><td align="left" valign="middle">Samples neutralizing</td><td align="right" valign="middle">182</td><td align="right" valign="middle">139</td><td align="right" valign="middle">144</td><td align="right" valign="middle">104</td><td align="right" valign="middle">104</td><td align="right" valign="middle">50</td><td align="right" valign="middle">63</td></tr><tr><td align="left" valign="middle">Percent neutralizing</td><td align="right" valign="middle">99</td><td align="right" valign="middle">63</td><td align="right" valign="middle">78</td><td align="right" valign="middle">76</td><td align="right" valign="middle">64</td><td align="right" valign="middle">50</td><td align="right" valign="middle">75</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p id="P22">Pre-Alpha CCP from 27 different studies had a GM (GMT<sub>50</sub>) of 311 from 707 samples with 315 or 45% neutralizing omicron BA.1(4).</p></fn><fn id="TFN2"><label>**</label><p id="P23">percent neutralizations after CoronaVac and Omicron COVID-19 in the paper by Cao <italic>et al</italic> could not be retrieved from the manuscript. 237 samples from the 6 other cohorts were used for percent neutralization.</p></fn></table-wrap-foot></table-wrap></floats-group></article>